Paper30050331
A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.
Li Y and 7 others. Clin Pharmacol, 2018. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension. Papers, record 30050331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30050331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23203815 | Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. | Cancer Chemother Pharmacol | 2013 | https://conductscience.org/library/papers/23203815 | PubMed |
| 2 | 17517289 | Recovery from postsurgical swallowing dysfunction in patients with oral cancer. | J Oral Maxillofac Surg | 2007 | https://conductscience.org/library/papers/17517289 | PubMed |
| 3 | 23961770 | Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. | Expert Opin Drug Metab Toxicol | 2013 | https://conductscience.org/library/papers/23961770 | PubMed |
| 4 | 24421329 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. | Blood | 2014 | https://conductscience.org/library/papers/24421329 | PubMed |
| 5 | 11753617 | Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. | Leukemia | 2001 | https://conductscience.org/library/papers/11753617 | PubMed |
| 6 | 25047979 | Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. | Leuk Res | 2014 | https://conductscience.org/library/papers/25047979 | PubMed |
| 7 | 11049970 | Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. | Blood | 2000 | https://conductscience.org/library/papers/11049970 | PubMed |
| 8 | 18805433 | The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. | Microvasc Res | 2009 | https://conductscience.org/library/papers/18805433 | PubMed |
| 9 | 1778094 | Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. | Dysphagia | 1991 | https://conductscience.org/library/papers/1778094 | PubMed |
| 10 | 12036884 | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. | Blood | 2002 | https://conductscience.org/library/papers/12036884 | PubMed |
| 11 | 25556560 | Population pharmacokinetics of pomalidomide. | J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25556560 | PubMed |
| 12 | 22205548 | Swallowing dysfunction in cancer patients. | Support Care Cancer | 2012 | https://conductscience.org/library/papers/22205548 | PubMed |
| 13 | 12666243 | Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline. | Chirality | 2003 | https://conductscience.org/library/papers/12666243 | PubMed |
| 14 | 23944852 | An occupational therapy program for patients with swallowing dysfunction following cancer treatment. | Occup Ther Health Care | 1986 | https://conductscience.org/library/papers/23944852 | PubMed |
| 15 | 15638853 | Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. | Br J Haematol | 2005 | https://conductscience.org/library/papers/15638853 | PubMed |
| 16 | 18392823 | Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. | Cancer Immunol Immunother | 2008 | https://conductscience.org/library/papers/18392823 | PubMed |
| 17 | 24007748 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Lancet Oncol | 2013 | https://conductscience.org/library/papers/24007748 | PubMed |
| 18 | 10384139 | Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. | J Immunol | 1999 | https://conductscience.org/library/papers/10384139 | PubMed |
| 19 | 29670410 | Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. | Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29670410 | PubMed |
| 20 | 24833703 | Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers. | J Pharmacol Exp Ther | 2014 | https://conductscience.org/library/papers/24833703 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42814376 | Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking. | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/42814376 | PubMed |
| 36106110 | Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. | Front Oncol | 2022 | https://conductscience.org/library/papers/36106110 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30050331
GET https://conductscience.org/api/papers/v1/30050331/references?page=2